UBS says AstraZeneca can reach 2030 revenue target
UBS analysts said AstraZeneca can meet its 2030 revenue target even if a highly anticipated lung-cancer clinical trial fails, and continue growing afterward.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.